Most people regain weight. A 2026 BMJ meta-analysis of 37 studies found an average regain of 0.4 kg a month after stopping weight-management medicines, with cardiometabolic markers projected back to baseline within 1.4 years. In SURMOUNT-4 (2024), people switched from tirzepatide to placebo regained 14% in a year. Exercise and planned eating reduce, but do not prevent, regain.
Why people stop
People come off GLP-1 medicines for many reasons: side effects, cost, insurance changes, supply problems, pregnancy plans, reaching a goal, or simply not wanting to inject indefinitely. Some health systems also set limits. In England, NICE recommends semaglutide for weight management for a maximum of two years, within a specialist weight management service, and suggests considering stopping if less than 5% of initial weight has been lost after six months (NICE TA875). For tirzepatide, NICE sets no fixed maximum but asks prescribers to decide whether to continue if less than 5% has been lost after six months on the highest tolerated dose (NICE TA1026).
Whatever the reason, the decision to stop, pause or reduce the dose should be made with your prescriber. This article explains what the evidence shows happens next, so you can plan for it.
Will I gain weight after stopping?
The randomised trials all point the same way.
| Trial | Treatment before stopping | What happened after stopping |
|---|---|---|
| STEP 1 extension | 68 weeks of semaglutide 2.4 mg plus lifestyle programme; average loss 17.3% | Regained 11.6 percentage points in the next year; net loss 5.6% at week 120 |
| STEP 4 | 20 weeks of semaglutide; average loss 10.6% | Switched to placebo: +6.9% over 48 weeks; stayed on drug: a further −7.9% |
| SURMOUNT-4 | 36 weeks of tirzepatide; average loss 20.9% | Switched to placebo: +14.0% over 52 weeks; stayed on drug: a further −5.5% |
| S-LiTE follow-up | Low-calorie diet, then a year of liraglutide, exercise, both or placebo | Regain after liraglutide alone was 6.0 kg greater than after exercise alone |
Semaglutide
In the STEP 1 extension, 327 participants were followed for a year after both semaglutide and the lifestyle programme stopped at week 68. The authors summarised the result as regaining two-thirds of the weight previously lost, with most cardiometabolic improvements reverting towards baseline (Wilding and colleagues, Diabetes Obes Metab 2022). People still ended up 5.6% lighter than when they started, on average.
STEP 4 tested the question directly. After a 20-week run-in on semaglutide, 803 participants were randomised to continue or switch to placebo. The gap between the groups at week 68 was 14.8 percentage points, and continuing treatment also kept waist size, blood pressure and physical functioning scores better (Rubino and colleagues, JAMA 2021).
Tirzepatide
SURMOUNT-4 randomised 670 people who had lost an average of 20.9% over 36 weeks on tirzepatide. By week 88, 89.5% of those who continued had kept at least 80% of their weight loss, against 16.6% of those switched to placebo (Aronne and colleagues, JAMA 2024). Even so, the placebo group remained 9.9% below their starting weight overall.
Across all studies
A 2026 BMJ systematic review included 37 studies and 9,341 participants. Weight came back at an average of 0.4 kg a month after medication stopped, and all cardiometabolic markers were projected to return to baseline within 1.4 years. Regain was faster after medicines than after behavioural weight-management programmes, by 0.3 kg a month, regardless of how much weight had been lost (BMJ 2026). The authors advised caution about short-term use of these drugs without a more comprehensive approach.
Not everyone regains the same amount
Averages hide a wide spread. A post hoc analysis of SURMOUNT-4 grouped 308 people who had lost at least 10% on tirzepatide and were then switched to placebo by how much they regained (JAMA Internal Medicine 2026). Fifty-four regained less than a quarter of what they had lost, 77 regained a quarter to a half, 103 regained half to three-quarters and 74 regained three-quarters or more. In the group that regained least, waist size, non-HDL cholesterol and fasting insulin a year later were not significantly different from when they stopped.
So stopping does not doom everyone to full regain. It does mean most people should expect some, and the analysis cannot tell us in advance who will do well. It was funded by the manufacturer and was not designed to test any particular maintenance strategy.
What happens to appetite and blood sugar
Appetite
Appetite coming back is the expected consequence of stopping. These medicines reduce appetite while they are being taken, and that effect does not persist once the drug has left the body. A 2026 review of the biology of regain points to the return of appetite after GLP-1 signalling is withdrawn, compensatory rises in hunger hormones such as ghrelin, and other adaptive changes, though it notes that evidence for some of these mechanisms is limited (Diabetes Obes Metab 2026). On top of that, a smaller body needs less energy than it did before weight loss, so eating your old portions brings weight back faster.
Blood sugar and other markers
In STEP 1 and SURMOUNT-4, HbA1c, blood pressure and cholesterol improved during treatment and moved back as weight returned. In the SURMOUNT-4 analysis, rises in HbA1c, blood pressure and waist size were larger in people who regained more. If you have type 2 diabetes or prediabetes, stopping a medicine that lowers glucose is a medical decision: your prescriber may need to restart, adjust or add other diabetes treatment, and you will need closer glucose monitoring. Never stop a GLP-1 that was prescribed for diabetes without that conversation.
If you take insulin or a sulfonylurea, your doses may have been reduced when you started a GLP-1. Stopping the GLP-1 can push blood glucose up, while restarting it later can push it down. Any change in diabetes medicines must come from your prescriber.
How to come off a GLP-1 safely
There is no evidence-based tapering schedule for semaglutide or tirzepatide in weight management, and the labels do not describe one. A 2026 perspective in Obesity Pillars notes that continued medication has the strongest direct evidence for limiting regain, and lists options such as monitored dose reduction with agreed re-escalation criteria, reduced-frequency dosing and structured lifestyle support as strategies still to be tested (Obesity Pillars 2026). Some prescribers step the dose down; others stop. Either way, these steps help:
- Plan before you stop. Agree a date with your prescriber, and set up follow-up appointments and weigh-ins for the following year.
- Agree a trigger point. Decide in advance what amount of regain would prompt a review, and what the options would be: restarting, another medicine, or more intensive support.
- Have the nutrition plan in place first. The habits below should be established while appetite is still controlled, not started once hunger returns.
- Do not restart old doses on your own. The Wegovy label explains that after missed doses the dose escalation may need to restart at a lower dose; the same caution applies after a longer break. Restarting at a high dose can bring back nausea and vomiting.
The nutrition plan that limits regain
The joint advisory issued in 2025 by four US obesity and nutrition societies is candid: structured nutrition and lifestyle therapy designed to prevent regain after stopping GLP-1 medicines has not yet been tested in controlled trials (Obesity Pillars 2025). The advice below is based on what does work for weight maintenance in general, and on the trial evidence we have.
Recalculate your energy needs
You now weigh less, so you need less energy than before you started treatment. Our calorie calculator gives a starting estimate for your current weight. Eating back to your pre-treatment portions is the most predictable route to regain.
Keep protein high
Protein is the most filling macronutrient and helps protect muscle, which supports your energy needs. The advisory's range during weight reduction is 1.2 to 1.6 g/kg; in maintenance, a dietitian can set a figure that suits you. Use the protein calculator as a guide, and build each meal around a protein food.
Fill up on fibre and volume
Vegetables, fruit, pulses, whole grains and soups add bulk for relatively little energy. They matter more once the medicine is no longer doing the job of making you feel full. Increase them gradually if you had gut side effects on treatment; our guide to easing GLP-1 nausea and constipation covers that.
Keep the structure you built
Regular meals, planned snacks, smaller plates and eating slowly are worth keeping. Our 7-day GLP-1 diet plan can be adapted for maintenance by increasing portions slightly. Some people find one structured meal replacement a day helps; the evidence for that is covered in our guide to meal replacement shakes.
Monitor, gently
The advisory lists self-monitoring of weight and food intake among the behaviours associated with keeping weight off. A weekly weigh-in at the same time of day is enough. The point is to notice a trend early and act, not to react to daily fluctuations.
Exercise: the strongest non-drug protector
The best randomised evidence for keeping weight off after a GLP-1 comes from S-LiTE. After an eight-week low-calorie diet, adults were randomised to a year of liraglutide, supervised exercise, both, or placebo, and were followed up a year after all treatment stopped. Weight regain in that year was 6.0 kg greater after liraglutide alone than after exercise alone, and people who had received the combination had 4.2 times the odds of those who had received liraglutide alone of still keeping off at least 10% of their initial weight (Jensen and colleagues, eClinicalMedicine 2024). The trial used liraglutide, an older daily GLP-1, so the results may not translate exactly to newer drugs.
NICE advises that people who have lost weight may need 60 to 90 minutes of activity a day to avoid regaining it (NICE NG246). That sounds a lot, but it includes walking, cycling, housework and active travel, not only formal exercise. Resistance training to protect muscle is also worth keeping, for reasons explained in our article on GLP-1 medicines and muscle loss.
Book a session with a dietitian
Can you maintain weight loss after GLP-1s?
Some people do, and the SURMOUNT-4 analysis shows that a minority regain little in the first year. But the trials say clearly that obesity behaves like a long-term condition, and that for many people the medicine is doing work that diet and willpower alone cannot fully replace. That is not a personal failure. NICE's obesity guideline asks professionals to explain that weight regain may happen in many cases and, for intensive diets, that regain does not mean the person or their clinician has failed.
The most realistic way to think about maintenance is a combination of options, reviewed over time:
- Continuing the medicine, if it is effective, tolerated, affordable and appropriate.
- Lifestyle support, including dietitian follow-up and a structured activity programme.
- Restarting or switching treatment if regain passes an agreed threshold.
- Other treatments, such as bariatric surgery, for people who meet the criteria.
Our guides to GLP-1 weight loss and medical weight loss set out the wider options, and our weight management hub links to them all.
Stopping for pregnancy, and other situations needing extra care
Planning a pregnancy. The Wegovy label on DailyMed says semaglutide should be stopped when pregnancy is recognised, and stopped two or more months ahead of a planned pregnancy because it is cleared from the body slowly. The aim during pregnancy changes from weight loss to healthy eating and activity: the NHS advises people with obesity not to try to lose weight while pregnant (NHS). Some weight gain after stopping is expected in this situation, and a dietitian or midwife can help you plan meals that support the pregnancy without fixating on the scale.
A history of disordered eating. Watching weight return can be distressing, and rigid attempts to stop it, such as skipping meals or very low intakes, can trigger or worsen disordered eating. The 2025 joint advisory recommends screening for eating disorders as part of GLP-1 care. If you notice preoccupation with food, guilt after eating or compensating behaviours, ask for specialist support early.
Older adults. Regain combined with lost muscle is a poor trade. Keeping up protein and resistance exercise matters more after 60, both while on treatment and after stopping.
People with kidney disease or heart failure. Changes in weight, fluid and blood pressure after stopping may affect other medicines, so ask your care team when follow-up checks should happen.
Losing access in the United States
Many US patients stop because of coverage rather than choice. The Medicare GLP-1 Bridge, launched on 1 July 2026, offers eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay, but it is a time-limited demonstration due to end on 31 December 2027, and the CMS page does not mention nutrition support. People relying on it should plan now for what happens if access ends. Our United States country guide explains how to find and pay for dietitian care.
The practical takeaway
Stopping a GLP-1 medicine usually brings weight back, often half or more of what was lost within a year, along with rises in blood pressure, cholesterol and blood glucose. Some people regain far less. The best-supported ways to limit regain are regular exercise, a nutrition plan built before you stop, and an agreed follow-up plan with your prescriber, including what you will do if weight returns.
Frequently asked questions
Will I gain weight after stopping Ozempic?
Most people do. In the STEP 1 extension, people regained about two-thirds of the weight lost on semaglutide within a year of stopping, and a 2026 BMJ meta-analysis found average regain of 0.4 kg a month after weight-management medicines. The amount varies widely, and exercise, a planned diet and follow-up can reduce it.
How to come off a GLP-1 safely
Agree the plan with your prescriber, who may step the dose down or stop. There is no tested tapering schedule. Set up follow-up appointments and a weight threshold that would prompt a review, establish a high-protein, high-fibre eating pattern and regular exercise before stopping, and do not restart at your old dose without advice.
Can you maintain weight loss after GLP-1s?
Some people can. In a SURMOUNT-4 analysis, 54 of 308 people switched to placebo regained less than a quarter of their lost weight within a year. Most regain more. People who had exercised during treatment in the S-LiTE trial kept off more weight a year after stopping. Ongoing support and an agreed plan for regain improve the odds.
How quickly does weight come back after stopping?
In the 2026 BMJ meta-analysis, the average was 0.4 kg a month, faster than after behavioural programmes. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight over 52 weeks. The appetite-reducing effect fades once the medicine leaves the body, which is why having eating habits in place before stopping is important.
Does blood sugar go up after stopping a GLP-1?
It can. In the trials, HbA1c and other cardiometabolic markers improved on treatment and moved back towards baseline as weight returned, with bigger rises in people who regained more. If you have type 2 diabetes, stopping must be planned with your prescriber, who may need to adjust or add other diabetes medicines.
Is it safe to stop a GLP-1 suddenly?
The main risks of stopping suddenly without a plan are faster regain and, in diabetes, a rise in blood glucose. Always discuss it with your prescriber first, so that follow-up, a nutrition plan and any other medicines are arranged. If you stop because of severe side effects such as suspected pancreatitis, seek medical advice straight away.
